Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2025-12-24 @ 11:16 PM
NCT ID:
NCT05356156
Eligibility Criteria:
Inclusion Criteria:
* Aged 18-75 years；
* Primary lesion is diagnosed with endometrial biopsy as adenocarcinoma of the stomach or esophagogastric junction, including: papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly cohesive carcinoma (including signet ring cell carcinoma and other variants), mixed adenocarcinoma, etc.；
* The gastric primary lesion is located in the antrum, body or fundus of stomach or the esophagogastric junction. It is expected that radical gastrectomy with D1+/D2 lymph node dissection achieves R0 resection (multiple primary cancers are also applicable)；
* BMI(Body Mass Index) \< 30 kg/m2；
* No history of upper abdominal surgery (except for laparoscopic cholecystectomy)；
* No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.；
* Preoperative ECOG (Eastern Cooperative Oncology Group) performance status score 0 or 1；
* Preoperative ASA (American Society of Anesthesiologists) scoring I-III；
* Sufficient vital organ functions；
* Signed informed consent.
Exclusion Criteria:
* Women during pregnancy or lactation；
* Suffer from other malignant tumors within 5 years；
* Preoperative body temperature ≥ 38°C or complicated with infectious diseases requiring systemic treatment；
* Severe mental illness；
* Severe respiratory disease；
* Severe liver and kidney dysfunction；
* History of unstable angina or myocardial infarction within 6 months；
* History of cerebral infarction or cerebral hemorrhage within 6 months；
* Continuous application of glucocorticoid within 1 month (except for topical application)；
* Accompanied by gastric cancer complications (bleeding, perforation, obstruction, etc.) ；
* The patient has participated in or is participating in other clinical studies (within 6 months).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT05356156
Study Brief:
Protocol Section:
NCT05356156